Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.

  • Revenue in EUR (TTM)238.28m
  • Net income in EUR-189.73m
  • Incorporated1998
  • Employees524.00
  • Location
    MorphoSys AGSemmelweisstr. 7PLANEGG 82152GermanyDEU
  • Phone+49 89899270
  • Fax+49 8 989927222
  • Websitehttps://www.morphosys.com
More ▼

Institutional shareholders

45.52%Per cent of shares held by top holders
HolderShares% Held
Kynam Capital Management LPas of 13 Mar 20244.19m11.13%
Goldman Sachs & Co. LLC (Private Banking)as of 29 Feb 20244.14m11.00%
Adage Capital Management LPas of 22 Jan 20241.89m5.02%
DWS Investment GmbHas of 18 Mar 20241.52m4.03%
RP Management LLC (Investment Management)as of 16 Feb 20241.34m3.55%
The Vanguard Group, Inc.as of 07 Mar 20241.25m3.32%
Caligan Partners LPas of 28 Feb 20231.06m2.81%
Baillie Gifford & Co.as of 16 Dec 2022835.29k2.22%
BlackRock Fund Advisorsas of 07 Mar 2024462.54k1.23%
Norges Bank Investment Managementas of 31 Dec 2023459.29k1.22%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.